ACTIVIDAD CIENTÍFICA

Artículos de investigación publicados en los últimos 5 años.

Agrupados por patologías.

1. Enfermedades raras del ritmo cardiaco (canalopatías) en adultos.

1. Serratosa-Fernández L, Pascual-Figal D, Masiá-Mondéjar MD, et al; Grupo de Cardiología del Deporte  de la Sociedad Española de Cardiología. Comments on the New International Criteria for Electrocardiographic Interpretation in Athletes. Rev Esp Cardiol. 2017 Nov;70(11):983-990. PubMed PMID: 28928069.   

2. Moreno C, Oliveras A, Bartolucci C, et al. D242N, a K(V)7.1 LQTS mutation uncovers a key residue for I(Ks) voltage dependence. J Mol Cell Cardiol. 2017 Sep;110:61-69. PMID: 28739325.  

3. Groba-Marco MD, Benito-Bartolomé F, García-Aguado M et al. The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. Rev Esp Cardiol. 2016; 69 (7): 702-4. PMID: 27198127

4. Anguera I, García-Alberola A, Dallaglio P et al. Shock Reduction With Long-Term Quinidine in Patients With Brugada Syndrome and Malignant Ventricular Arrhythmia Episodes. J Am Coll Cardiol. 2016; 67(13):1653-4. PMID: 27150692.

5. Gimeno-Blanes FJ, Blanco-Velasco M, Barquero-Pérez Ó, et al. Sudden Cardiac Risk Stratification with Electrocardiographic Indices - A Review on Computational Processing, Technology Transfer, and Scientific Evidence. Front Physiol. 2016 Mar 7;7:82. PMID: 27014083.

6. García-Molina E, Sabater-Molina M, Muñoz C, et al. An R1632C variant in the SCN5A gene causing Brugada syndrome. Mol Med Rep. 2016; 13(6): 4677-80. PMID: 27082542

7. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E et al. Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms. Rev Esp Cardiol 2016; 69(3): 300-9. PMID: 26856793.

8. Jiménez-Jáimez J, Peinado R, Grima EZ et al. Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). Am J Cardiol. 2015 Sep 15;116(6):894-9. PMID: 26189708

9. Moreno C, Oliveras A, de la Cruz A et al. A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. Cardiovasc Res. 2015 Sep 1;107(4):613-23. PMID: 26168993.

10. Mogensen J, van Tintelen JP, Fokstuen S et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J. 2015 Jun 7;36(22):1367-70. PMID: 25845928

11. Muñoz-Esparza C, García-Molina E, Salar-Alcaraz M, et al. Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. Rev Esp Cardiol. 2015; 68(10): 861-8. PMID: 25819988

12. García-Molina E, Lacunza J, Ruiz-Espejo F, Sabater M, García-Alberola A, Gimeno JR, Cañizares F, García A, Martínez P, Valdés M, Tovar I. A study of the SCN5A gene in a cohort of 76 patients with Brugada syndrome. Clin Genet. 2013; 83(6):530-8. PMID: 22984773

13. Sabater M, García-Molina E, Tovar I, et al. Cost-effectiveness of genetic studies in inherited heart diseases. Cardiogenetics 2013; vol3 , e5.

14. Gimeno JR, Lacunza J, García-Molina E, et al. Short QT and dilated cardiomyopathy. A phenotype with a good prognosis?. Int J Cardiol. 2011 Sep 15;151(3):356-7. PMID: 21794937

15. Monserrat L, Mazzanti A, Ortiz-Genga M, et al. The interpretation of genetic tests in inherited cardiovascular diseases. Cardiogenetics 2011; Vol 1:e8.

16. Gimeno JR, Oliva MJ, Lacunza J, et al. Characteristics of sudden cardiac death in inherited heart disease. Rev Esp Cardiol 2010; 63(3):268-76. PMID: 20196987

17. Arnau MA, Domingo D, Sanz-Sánchez J, Gimeno JR, Zorio E. Book ¿Practical management of arrhythmias¿. Book Chapter.¿Long QT syndrome¿. Editor: Sociedad Española de Cardiología 2016, Elsevier.

 

2. Enfermedades raras del ritmo cardiaco (canalopatías) en pacientes pediátricos (se incluyen publicaciones del apartado 1 y 3 que incluyen casos o información de casos en edad pediátrica.).

1. Groba-Marco MD, Benito-Bartolomé F, García-Aguado M et al. The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. Rev Esp Cardiol. 2016 May 16. [Epub ahead of print]. PMID: 27198127

2. Anguera I, García-Alberola A, Dallaglio P et al. Shock Reduction With Long-Term. Quinidine in Patients With Brugada Syndrome and Malignant Ventricular Arrhythmia. Episodes. J Am Coll Cardiol. 2016; 67(13):1653-4. PMID: 27150692.

3. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E et al. Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. Rev Esp Cardiol. 2016 feb 5. PMID: 26856793.

4. Jiménez-Jáimez J, Peinado R, Grima EZ et al. Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). Am J Cardiol. 2015 Sep 15;116(6):894-9. PMID: 26189708

5. Muñoz-Esparza C, García-Molina E, Salar-Alcaraz M, et al. Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. Rev Esp Cardiol. 2015; 68(10): 861-8. PMID: 25819988

6. García-Molina E, Lacunza J, Ruiz-Espejo F, et al. A study of the SCN5A gene in a cohort of 76 patients with Brugada syndrome. Clin Genet. 2013; 83(6):530-8. PMID: 22984773

7. Gimeno JR, Oliva MJ, Lacunza J, et al. Characteristics of sudden cardiac death in inherited heart disease. Rev Esp Cardiol 2010; 63(3):268-76. PMID: 20196987

8. Arnau MA, Domingo D, Sanz-Sánchez J, Gimeno JR, Zorio E. Book ¿Practical management of arrhythmias¿. Book Chapter.¿Long QT syndrome¿. Editor: Sociedad Española de Cardiología 2016, Elsevier [in press]

9. Sabater-Molina M, Navarro M, García-Molina E, Garrido I, Pascual-Figal D, González-Carrillo J, Gimeno JR. Mutation in JPH2 cause dilated Cardiomyopathy. Clin Genet. 2016 [in press]

10. Román IS, Navarro M, Martínez F et al. Unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in FHL1. Clin Genet. 2016 Feb 9. PMID: 26857240

11. García-Giustiniani D, Arad M, Ortíz-Genga M et al. Phenotype and prognostic correlations of the converter region mutations affecting the ¿ myosin heavy chain. Heart. 2015; 101(13): 1047-53. PMID: 25935763.

12. Sabater-Molina M, Guillén-Navarro E, García-Molina E et al. Barth syndrome in adulthood: a clinical case. Rev Esp Cardiol. 2013 66(1):68-70. PMID: 22999963.

13. Oliva-Sandoval MJ, Muñoz-Esparza C, García-Molina E, et al. Hypertrophic cardiomyopathy or storage cardiomyopathy? Role of genetics to predict outcome. Int J Cardiol. 2011; 151(3): 380-1. PMID: 21783265

14. Oliva MJ, Ruiz F, Monserrat L, et al. Insights into Genotype-Phenotype correlation in Hypertrophic Cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart 2010; 96(24): 1980-4. PMID: 21088121.

 

3. Miocardiopatias familiares en adultos y en niños.

 

1. Santos Mateo JJ, Sabater Molina M, Gimeno Blanes JR. Hypertrophic cardiomyopathy. Med Clin (Barc). 2018; 150 (11): 434-442. PMID: 29150126. 

2. Perez-Sanchez I, Sabater-Molina M, Nicolás ME, et al. Phenotypic characterization of a family with an in-frame deletion in the DMD gene and variable penetrance. Curr Gene Ther. 2018 Jul 9. doi: 10.2174/1566523218666180709125346. [Epub ahead of print] PubMed PMID: 29984652. 

3. Pérez-Sánchez I, Romero-Puche AJ, García-Molina Sáez E, et al. Factores que influyen en la expresión fenotípica de la miocardiopatía hipertrófica en portadores genéticos. Rev Esp Cardiol. 2018 Mar;71(3):146-154. PMID: 28687478.

4. Sabater-Molina M, Pérez-Sánchez I, Hernández Del Rincón JP, et al. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet. 2018 Jan;93(1):3-14. PMID: 28369730. 

5. Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol. 2017 Dec 1;248:232-238. PMID: 28811092. 

6. Sabater-Molina M, Saura D, García-Molina Sáez E, González-Carrillo J, Polo L,  Pérez-Sánchez I, Olmo MD, Oliva-Sandoval MJ, Barriales-Villa R, Carbonell P, Pascual-Figal D, Gimeno JR. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. Rev Esp Cardiol. 2017 Feb;70(2):105-114. PMID: 28029522.

7. O´Mahony C, Jichi F, Monserrat L et al. Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricular wall thickness in Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2016; 9: e003818. DOI: 10.1161/CIRCEP.115.003818) [Epub ahead of print]. PMID: 27217341

8. Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, et al. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant. 2016 May;35(5):625-35. PMID: 26899768.

9. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016 Jun 14;37(23):1850-8. PMID: 26792875.

10. San Román I, Rodríguez ME, Caporossi O, et al. Computer Assisted Retinal Vessel Tortuosity Evalution in Novel Mutation Fabry Disease: Towards New Prognostic Markers. Retina. 2017 Mar;37(3):592-603. PMID: 28225726. 

11. Sabater-Molina M, Navarro M, García-Molina E, Garrido I, Pascual-Figal D, González-Carrillo J, Gimeno JR. Mutation in JPH2 cause dilated Cardiomyopathy. Clin Genet. 2016 [in press]

12. Román IS, Navarro M, Martínez F et al. Unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in FHL1. Clin Genet. 2016 Feb 9. PMID: 26857240

13. López-Cuenca D, Muñoz-Esparza C, Navarro Peñalver M et al. Hypertrophic or hypertensive cardiomyopathy? Int J Cardiol. 2016 Jan 15;203:891-2. PMID: 26609686

14. Elliott P, Charron P, Gimeno-Blanes JR et al. European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. Eur Heart J. 2016 Jan 7;37(2):164-73.

15. Pastor A, Petrillo F, Navarro M et al. How far do we want to go in the treatment of obstruction in Hypertrophic Cardiomyopathy? Int J Cardiol. 2015; 195: 95-7. PMID: 26025866

16. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E et al. Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms. Rev Esp Cardiol 2016; 69(3): 300-9. PMID: 26856793.

17. Pinto YM, Elliott PM, Arbustini E et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016 Jan 19. PMID: 26792875

18. Lopez-Ayala JM, Oliva-Sandoval MJ, Sanchez-Muñoz JJ et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2015; 385(9968): 662. PMID: 25706084

19. López-Ayala JM, Boven L, van den Wijngaard A et al. Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation. Rev Esp Cardiol. 2015; 68(4):346-9. PMID: 25700660.

20. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015 Apr;12(4):766-73. PMID: 25616123

21. Guttmann OP, Pavlou M, O'Mahony C et al. Hypertrophic Cardiomyopathy Outcomes Investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail. 2015; 17(8): 837-45. PMID: 26183688.

22. García-Giustiniani D, Arad M, Ortíz-Genga M et al. Phenotype and prognostic correlations of the converter region mutations affecting the ¿ myosin heavy chain. Heart. 2015; 101(13): 1047-53. PMID: 25935763.

23. Pastor Quirante FA; Pastor-Pérez FJ; Manzano-Fernández S; et al. Unexpected autopsy findings after sudden cardiac death: Cardiovascular myxoedema and endocardial fibroelastosis. Int J Cardiol 182 (2015) 281¿283. PMID: 25585372.

24. O'Mahony C, Jichi F, Pavlou M et al Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014 7; 35(30): 2010-20. PMID: 24126876.

25. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J. 2014; 35(39):2733-79. PMID: 25173338.

26. Ristic A, Imazio M, Adler Y et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2014; 35(34):2279-84. PMID: 25002749.

27. San Román I, Moreno-Flores V, López-Cuenca D et al . Comprehensive clinical evaluation of a large Spanish Anderson-Fabry family with novel GLA mutation and severe cardiac phenotype. Medicina Clínica. 2014; 142(11): 497-504. PMID: 24679964.

28. López-Ayala JM, Gómez-Milanés I, Sánchez-Muñoz JJ, et al. Desmoplakin truncations and left ventricular arrhythmogenic cardiomyopathy: characterizing a phenotype. Europace. 2014 2014 Dec;16(12):1838-46. PMID 24938629

29. Lopez-Ayala JM, Gomez I, Navarro M, et al. A mutation in the Z-line cypher/ZASP protein is associated with arrhythmogenic right ventricular cardiomyopathy. Clin Genet. 2015; 88 (2): 172-6. PMID: 25041374.

30. Lopez-Ayala JM, Gimeno JR. Author's reply. Desmoplakin truncations and left ventricular arrhythmogenic cardiomyopathy: characterizing a phenotype. Europace. 2014; 16(12):1838-46. PMID 24938629

31. Caforio ALP, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis. A Position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013. 34(33):2636-48. PMID: 23824828.

32. Sabater-Molina M, Guillén-Navarro E, García-Molina E et al. Barth syndrome in adulthood: a clinical case. Rev Esp Cardiol. 2013 66(1):68-70. PMID: 22999963.

33. De la Morena G, Caro C, Saura D, et al. Exercise Eco-Doppler in Hypertrophic Cardiomyopathy Patients. Determinant Factors of Exercise Intolerance. Rev Esp Cardiol. 2013 66(2):98-103. PMID: 24775382.

34. Gimeno JR, Tomé MT, McKenna WJ. Alcohol septal ablation in hypertrophic cardiomyopathy: an opportunity to be taken. Rev Esp Cardiol 2012; 65(4):314-8. PMID: 22381943

35. Luxán G, Casanova JC, Martínez-Poveda B, et al. Mutations in the NOTCH pathway regulator MIB1 cause left ventricular non-compaction Cardiomyopathy. Nat Med 2013, 19, 193-201. PMID: 23314057.

36. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A Position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34(19):1448-58. PMID: 23211230.

37. Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013 ; 34(32): 2529-37. PMID: 23455360

38. Núñez L1, Gimeno-Blanes JR, Rodríguez-García MI, Monserrat et al. Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circ J. 2013;77(9):2358-65. PMID: 23782526.

 

Participación del grupo en elaboración de guías de práctica clínica y desarrollo de herramientas tecnológicas.

1. Charron P, Elliott PM, Gimeno JR, et al; EORP Cardiomyopathy Registry Investigators . The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018 Jan 24. doi: 10.1093/eurheartj/ehx819. [Epub ahead of print] PubMed PMID: 29378019. 

2. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016 Jan 19. [Epub ahead of print] PMID: 26792875

3. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E et al. Protocolo de actuación en las cardiopatías familiares: síntesis de recomendaciones y algoritmos de actuación. Rev Esp Cardiol. 2016 feb 5. PMID: 26856793.

4. Elliott P, Charron P, Gimeno-Blanes JR et al. European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. Eur Heart J. 2016 Jan 7;37(2):164-73.

5. Bernabé G, González-Carrillo J, Cuenca J, et al. Performance of a new software for automatic quantification of left ventricular trabeculations. Rev Esp Cardiol 2016, [in press]

6. O¿Mahony C, Jichi F, Monserrat L et al. Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricular wall thickness in Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2016; 9: [Epub ahead of print]. PMID: 27217341

7. Bernabé G, Cuenca J, Teruel PEL et al. Software tool for the automatic quantification of the left ventricle myocardium hyper-trabeculation degree. Procedia Comput Sci. 2015; 51: 610-9.

8. Guttmann OP, Pavlou M, O'Mahony C et al. Hypertrophic Cardiomyopathy Outcomes Investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail. 2015; 17(8): 837-45. PMID: 26183688.

9. O'Mahony C, Jichi F, Pavlou M et al Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014 7; 35(30): 2010-20. PMID: 24126876.

10. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J. 2014; 35(39):2733-79. PMID: 25173338.

10. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A Position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 May;34(19):1448-58. PMID: 23211230.

Tenemos colaboraciones activas con otros grupos a nivel internacional para el desarrollo de proyectos multicéntricos: HCM-Risk consortium y Registro Europeo de Miocardiopatias y miocarditis (http://www.escardio.org/Guidelines-&-Education/Trials-and-Registries/Observational-registries-programme/Cardiomyopathy-and-Myocarditis-Registry)

 

Lista de proyectos de investigación de los ultimos 5 años.

1. "Estudio de mutaciones somáticas en genes sarcoméricos en la Miocaridiopatía Hipertrófica.¿. Entidad Financiadora: Fundacion para la Investigacion Sanitaria. Insituto de Salud Carlos III. FIS. PI081469. Investigador principal: Juan R. Gimeno. Centros participantes: Hospital Universitario Virgen de la Arrixaca. Hospital Juan Canalejo de La Coruña. Hospital Reina Sdeía. Hospital Virgen del Rosell. Hospital General Universitario de Alicante. Hospital General de Valencia. Legal and Forensic Medicine Institute de Murcia, Alicante and Valencia. 2009-2012. Presupuesto: 210,000.

2. "Study de suden death causes in the Region de Murcia. First phase de a multidisciplinary project for a Regional Prevention and Management de Sudden Cardiac Death Unit (Pheidippides Project)". Entidad Financiadora: Séneca. Investigador Principal: Juan R. Gimeno. Centros participantes: Hospital Universitario Virgen de la Arrixaca. Instituto de Medicina Legal de Murcia, Hospital Reina Sdeía. Hospital virgen del Rosell, Hospital de los Arcos, Hospital Morales Meseguer, Hospital Rafael Méndez. 2009-2011.

3. "Clinical, genetic and functional study de the channelopathies". Entidad Financiadora: Fundacion para la Investigacion Sanitaria. Insituto de Salud Carlos III. FIS. PI11/02459. Investigador Principal: Juan R. Gimeno. Centros participantes: Hospital Universitario Virgen de la Arrixaca. Instituo de Medina Legal de Murcia, Hospital Reina Sofía, Hospital La Fe de Valencia, Centro Superior de Investigación Científica de Madrid, Universidad Autónoma de Barcelona, Universidad Rey Juan Carlos de Madrid. 2012-2014.

4. "Investigating genetic and mechanistic interactors in familial cardiomyopathy through advanced disease modeling". Entidad Financiadora: Fundació Marató TV3. Investigadores Principales: Angel Raya, Jose Luis de la Pompa, Juan Ramón Gimeno. Centros participantes: Institut de Bioenginyeria de Catalunya. Centro Nacional de Investigación Cardiovascular (ISCIII). Hospital Universitario Virgen de la Arrixaca. 2016-18.

5. "Mechanistic and genetic interactions in Familial Cardiomyopathy through advance disease modeling", Entidad Financiadora: Fundacion para la Investigacion Sanitaria. Insituto de Salud Carlos III. Convocatoria de redes de investigacion de excelencia. Investigador Principal: José Luis de la Pompa. Centros participantes: Institut de Bioenginyeria de Catalunya. Centro Nacional de Investigación Cardiovascular (CNIC). Hospital Universitario Virgen de la Arrixaca. Hospital Puerta de Hierro. Universidad de Málaga. 2016-17.

6. ¿Caracterizacion clínica, patologica, molecular y genética de la miocaridopatía arritmogénica. Diferencias entre la forma clásica (derecha) y la izquierda¿ Entidad Financiadora: Fundacion para la Investigacion Sanitaria. Insituto de Salud Carlos III. FIS. PI14/01676. Investigador Principal: Juan R. Gimeno. Centros participantes: Hospital Universitario Virgen de la Arrixaca. Hospital Reina Sofía. Hospital La Fe de Valencia. Instituto de Medicina Legal de Murcia y de Valencia. Instituto Nacional de Toxicología y Ciencias Forenses de Madrid. 2015-17.

7. "Fisiopatología de la Miocardiopatía Hipertrófica: de la clínica a los modelos animales¿. Entidad Financiadora: Sociedad Española de Cardiología y Fundación Española de Cardiología. Investigador Principal: Maria José Oliva. Centros participantes: Hospital Universitario Virgen de la Arrixaca: Servicio de Cardiología, Laboratorio de Cardiogentica (LAIB-IMIB), Platoforma de modelos animales (pez cebra) (IMIB). 2014-15.

8. "Caracterización genética de la Miocardiopatía Hipertrófica en gatos. Fase I para el desarrollo de un ensayo clínico¿. Entidad Financiadora: Sociedad Española de Cardiología y Fundación Española de Cardiología. Investigador Principal: Juan Ramón Gimeno. Centros participantes: Hospital Universitario Virgen de la Arrixaca (Murcia), Laboratorio de Cardiogenética (LAIB-IMIB), Centro de Bioquímica y Genética Clínica (Murcia), Hospital Clínico Veterinario de Murcia (Universidad de Murcia). 2016-17.  

9. "Oligonucleotidos antisentido como nueva estrategia terapéutica en la miocardiopatia
hipertrófica.¿. Entidad Financiadora: Sociedad Española de Cardiología y Fundación Española de Cardiología. Investigador Principal: María Sabater Molina. Centros participantes: Hospital Universitario Virgen de la Arrixaca (Murcia), Laboratorio de Cardiogenética (LAIB-IMIB), Centro de Bioquímica y Genética Clínica (Murcia), Hospital Clínico Veterinario de Murcia (Universidad de Murcia). 2018-19.  

10. " Caracterización de la miocardiopatía arritmogénica a partir de modelos en pez cebra y desarrollo de terapia génica.¿ Entidad Financiadora: Instituto de Salud Carlos III. FIS. PI18/01231. Investigador Principal: Juan R. Gimeno. Centros participantes: Hospital Universitario Virgen de la Arrixaca. Hospital Reina Sofía. Hospital La Fe de Valencia. Instituto de Medicina Legal de Murcia y de Valencia. Instituto Nacional de Toxicología y Ciencias Forenses de Madrid. 2019-21.